The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Hims & Hers (HIMS) stock plunged 27% on Tuesday after the telehealth high flyer confirmed it would soon stop offering some compounded versions of weight-loss drugs. The company's fourth quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback